Mr. Enyedy joined ImmunoGen as President and Chief Executive Officer in 2016, bringing over twenty-five years of combined general management, business development, and legal experience in the biotechnology industry. Prior to ImmunoGen, he served as Executive Vice President and Head of Corporate Development for Shire plc leading the company's Strategy, M&A, and Corporate Planning functions and providing commercial oversight for the company's pre-Phase 3 portfolio.
Previously, Mr. Enyedy served as CEO of Proteostasis Therapeutics, Inc., following 15 years at Genzyme Corporation in diverse roles, most recently as President of the Transplant, Oncology, and Multiple Sclerosis divisions. Before joining Genzyme, Mr. Enyedy was an associate with the law firm Palmer & Dodge. He holds a J.D. from Harvard Law School and a B.S. from Northeastern University. Mr. Enyedy also serves on the Board of Directors of Fate Therapeutics and Keryx Biopharmaceuticals.
Craig Barrows joined ImmunoGen in October 2007 with over twenty years of legal experience – thirteen as chief corporate legal officer – and a strong transactional background. Mr. Barrows was general counsel of M/A-COM, Inc. from 1994 until the company was acquired in 1996, general counsel and secretary of Media 100 Inc. before he joined New England Business Service, Inc. (NEBS) in 1998, and vice president, general counsel and secretary of NEBS until the company was acquired in 2004. Mr. Barrows was vice president, general counsel and assistant secretary of Mercury Computer Systems, Inc. Before transitioning to in-house counsel, Mr. Barrows focused on corporate and securities law at Skadden, Arps, Slate, Meagher & Flom. He earned his undergraduate degree at the University of Chicago and his law degree at Fordham University School of Law.
Dr. Gregory joined ImmunoGen in 2015 bringing over twenty-five years of scientific and research management experience, most of it gained in positions of increasing responsibility at Genzyme. In 2003, he was appointed the head of research at Genzyme, with responsibility for early research – from discovery to development – for all Genzyme therapeutic areas, including an ADC initiative. Following Sanofi’s acquisition of Genzyme in 2011, Dr. Gregory was appointed head of the Sanofi-Genzyme R&D Center and in that capacity was responsible for Genzyme R&D from discovery through regulatory approval. Richard received his doctorate in biochemistry from the University of Massachusetts at Amherst, followed by post-doctoral research in cancer genetics at the Worcester Foundation for Experimental Biology.
David Johnston joined ImmunoGen in December 2013 as EVP and CFO bringing to ImmunoGen more than 30 years of experience in corporate finance, including 15 years in senior financial functions at biotechnology companies, as well as extensive experience in corporate planning. Prior to joining ImmunoGen, Mr. Johnston was chief financial officer at AVEO Pharmaceuticals Inc. Prior to joining AVEO in 2007, he was Senior Vice President of Finance, Corporate Planning and Analysis at Genzyme Corporation and, before that, the VP Finance and CFO of Genzyme Biosurgery. Prior to joining Genzyme in 1998, Mr. Johnston held financial, planning and analysis positions of increasing responsibility at several major corporations. He holds a BS degree from Washington and Lee University and an MBA from the University of Michigan.
Berkenblit joined ImmunoGen in 2015 and is responsible for
leading the clinical development of ImmunoGen's novel, wholly owned product
candidates.She has extensive
experience in the clinical development of novel anticancer therapies, including
five years heading clinical research at two oncology-focused companies.
to joining ImmunoGen,Dr.
Berkenblitwas Senior Vice
President, Clinical Development atH3
Biomedicine, a developer of targeted anticancer compounds founded byEisai Pharmaceuticals. Prior toH3 Biomedicine, she was VP, Head of
Clinical Research at AVEO Oncology, where she led the clinical development of
oncology product candidates spanning early testing to registration trials.
Prior to AVEO, Dr. Berkenblit held positions of increasing responsibility at
Wyeth and then Pfizer, becoming Vice President, Neratinib Asset Team Leader in
the Pfizer Oncology Business Unit.
Berkenblitearned an MD degree
fromHarvard Medical School, and
an MMSc degree in the Clinical Investigator Training Program of Harvard/MIT
Health Sciences & Technology. She completed her internship and residency at
Brigham and Women's Hospital, then went on to a hematology/oncology fellowship
atBeth Israel Deaconess Medical
Center where she stayed on staff to focus on clinical research in GYN and GI
malignancies. She also led the Phase I oncology clinical trial program as part
of theDana-Farber/Harvard Cancer
Center, prior to transitioning to industry.
Dr. Ryll joined ImmunoGen in August 2015 as Vice President of Process and Analytical Development and took on leadership of Technical Operations in 2017. With 24 years of experience in bioprocessing, throughout his career he served in roles of increasing responsibility in process development, scale-up, manufacturing support, and development of scientific talent at Genentech, Abgenix, Tanox, and Biogen. Dr. Ryll obtained his doctorate in Biochemistry and Biotechnology from the Technical University of Braunschweig in Germany, developing cell culture based production processes for recombinant proteins and associated control approaches.
Dr. Wingrove joined ImmunoGen in early 2011 with over twenty years of regulatory and clinical management experience in the healthcare industry. Before joining ImmunoGen, she was the vice president of regulatory and clinical affairs at Histogenics, where her responsibilities included authoring and gaining approval of a SPA for a Phase III trial for a novel biologic and other regulatory responsibilities in the US and Europe. Prior to that, she was the senior director of regulatory and clinical affairs at MediSpectra, where she was responsible for the full spectrum of regulatory support – from start of clinical testing through marketing approval – for a novel cancer diagnostic product. Prior to joining MediSpectra, Dr. Wingrove was at Pfizer-Infusaid for over ten years, during which time she executed the clinical and regulatory programs associated with the company's combination products. She holds a BS in Biochemistry from Brown University and a doctorate in Biochemical Toxicology from the University of Rochester.